The present invention relates to a bifunctional chiral organocatalytic compound having excellent enantioselectivity, a preparation method therefor, and a method for producing a non-natural gamma amino acid from a nitro compound by using the chiral organocatalytic compound. According to the present invention, the bifunctional chiral organocatalytic compound having excellent enantioselectivity can be easily synthesized, gamma-amino acids with high optical selectivity can be obtained at a high yield by an economical and convenient method using the chiral organocatalytic compound, and various (R)-configuration gamma-amino acids, which are not present in nature, can be produced with high optical purity in large quantities by using a small amount of a catalyst, and therefore, the present invention can be widely utilized in various industrial fields including the pharmaceutical industry.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

This invention relates to compounds of Formula (I) wherein Cy.sup.1, L.sup.1, Y, R.sup.1, L.sup.2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. ##STR00001##

This invention relates to compounds of Formula (I) wherein Cy.sup.1, L.sup.1, Y, R.sup.1, L.sup.2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. ##STR00001##

The present invention describes method of preparation of esters or amides of lactyl lactates of general formula I, where Z denotes to group of R—O or RR′—N and R represent alkyl, aryl or H from lactide and the lactide is in contact with a hydrocarbyl alcohol and a hydrolyzable halide in a non-chlorinated organic solvent, or an amine initiated by a hydrolysable halide or hydrogen halide solution or an ammonium hydrohalide, wherein the hydrocarbyl alcohol or amine is either aliphatic or aromatic and containing 1 to 1000 carbon atoms, preferably 1 up to 150 carbon atoms, and optionally one or more, preferably 1 to 5, —CH.sub.2— groups may be replaced by —O— groups.

Structure for annotation

##STR00001##

The present invention describes method of preparation of esters or amides of lactyl lactates of general formula I, where Z denotes to group of R—O or RR′—N and R represent alkyl, aryl or H from lactide and the lactide is in contact with a hydrocarbyl alcohol and a hydrolyzable halide in a non-chlorinated organic solvent, or an amine initiated by a hydrolysable halide or hydrogen halide solution or an ammonium hydrohalide, wherein the hydrocarbyl alcohol or amine is either aliphatic or aromatic and containing 1 to 1000 carbon atoms, preferably 1 up to 150 carbon atoms, and optionally one or more, preferably 1 to 5, —CH.sub.2— groups may be replaced by —O— groups.

Structure for annotation

##STR00001##

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

##STR00001##

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.